News
03-09-2016, 11:32 AM
In light of conflicting and inconclusive clinical data on the benefit of radiation therapy in cancer patients with the BRCA1 and BRCA2 mutation, a clinical review examined the current status of data regarding BRCA1 and BRCA2 deficiency and radiation therapy sensitivity and a potential strategy to intensify the effects of radiation therapy (RT) by poly(ADP-ribose) polymerase inhibitors (PARPi), the pharmacologic drugs under investigation as monotherapy for the treatment of breast cancer in patients with BRCA1 and BRCA2 mutations.
More... (http://www.news-medical.net/news/20160309/Clinical-review-examines-benefit-of-RT-in-breast-cancer-patients-with-BRCA1-BRCA2-mutations.aspx)
More... (http://www.news-medical.net/news/20160309/Clinical-review-examines-benefit-of-RT-in-breast-cancer-patients-with-BRCA1-BRCA2-mutations.aspx)